| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Amino acid transporters (LAT1/ASCT2 substrate) [1]
|
|---|---|
| ln Vitro |
FSY-OSO2F exhibited time-dependent uptake in U87MG glioblastoma cells, reaching plateau at 60 min. Competitive inhibition assays with 2 mM leucine reduced uptake by 82%, confirming LAT1 transporter involvement [1]
|
| ln Vivo |
PET/CT imaging in U87MG xenograft mice showed rapid tumor uptake of FSY-OSO2F (peak SUV = 3.2 at 15 min post-injection). Tumor-to-muscle ratio reached 8.5 at 60 min, significantly higher than clinical tracer [18F]FET (ratio = 4.1, p<0.01) [1]
|
| Cell Assay |
Cellular uptake kinetics: U87MG cells seeded in 24-well plates (2×10⁵/well) incubated with FSY-OSO2F (37 kBq/well) at 37°C. Cells harvested at 2, 5, 15, 30, 60 min, washed with ice-cold PBS, lysed, and radioactivity measured by gamma counter. Results normalized to protein content [1]
Transporter inhibition: Cells pre-treated with 2 mM leucine for 30 min before adding FSY-OSO2F. Uptake measured after 15 min incubation [1] |
| Animal Protocol |
PET imaging: BALB/c nude mice with U87MG tumors (150-200 mm³) anesthetized and injected intravenously with FSY-OSO2F (5-7 MBq in 100 μL saline). Dynamic PET scans performed for 60 min. Biodistribution study conducted at 60 min post-injection (n=4) [1]
|
| ADME/Pharmacokinetics |
Blood clearance: Rapidly eliminated from the blood, with a half-life of 12.3 ± 1.5 minutes (initial phase) and 98.7 ± 10.2 minutes (terminal phase) [1] Biodistribution (60 minutes after intravenous injection): Tumor uptake: 4.32 ± 0.41 %ID/g Liver: 1.05 ± 0.12 %ID/g Kidney: 12.68 ± 1.53 %ID/g Muscle: 0.51 ± 0.07 %ID/g [1] Excretion: Primarily excreted via the kidneys, with 75.2 ± 6.3% of the injected dose excreted in the urine within 60 minutes [1]
|
| References | |
| Additional Infomation |
Blood clearance: Rapidly eliminated from the blood, with a half-life of 12.3 ± 1.5 minutes (initial phase) and 98.7 ± 10.2 minutes (terminal phase) [1] Biodistribution (60 minutes after intravenous injection): Tumor uptake: 4.32 ± 0.41 %ID/g Liver: 1.05 ± 0.12 %ID/g Kidney: 12.68 ± 1.53 %ID/g Muscle: 0.51 ± 0.07 %ID/g [1] Excretion: Primarily excreted via the kidneys, with 75.2 ± 6.3% of the injected dose excreted in the urine within 60 minutes [1]
|
| Molecular Formula |
C9H10FNO5S
|
|---|---|
| Molecular Weight |
263.24280500412
|
| Exact Mass |
263.026
|
| CAS # |
1839622-49-9
|
| PubChem CID |
118561836
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
358
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(O)(=O)[C@H](CC1=CC=C(OS(F)(=O)=O)C=C1)N
|
| InChi Key |
IVWVAUUBEKCCJQ-QMMMGPOBSA-N
|
| InChi Code |
InChI=1S/C9H10FNO5S/c10-17(14,15)16-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-fluorosulfonyloxyphenyl)propanoic acid
|
| Synonyms |
FSY-OSO2F; 1839622-49-9; (S)-2-Amino-3-(4-((fluorosulfonyl)oxy)phenyl)propanoic acid; (2S)-2-amino-3-{4-[(fluorosulfonyl)oxy]phenyl}propanoic acid; (2S)-2-AMINO-3-(4-[(FLUOROSULFONYL)OXY]PHENYL)PROPANOIC ACID; orb2566212; SCHEMBL17318149;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7988 mL | 18.9941 mL | 37.9881 mL | |
| 5 mM | 0.7598 mL | 3.7988 mL | 7.5976 mL | |
| 10 mM | 0.3799 mL | 1.8994 mL | 3.7988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
